Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Date:4/20/2012

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012.
Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 72346185.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on May 9, 2012, through 12:00 a.m. Eastern Time on May 16, 2012, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 72346185.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
3. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
5. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
6. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
7. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013   Polymer Technology Systems, Inc. ... Health Group to integrate the CardioChek ® ... administered by health systems across the country. The ... and distributed through Hanson Medical Systems , ... cholesterol, LDL cholesterol, triglycerides, and glucose. ...
(Date:6/17/2013)... Texas , June 17, 2013  Hanger, Inc. ... 5-year credit agreement that increases its senior secured facilities ... $400 million previously.  The new credit agreement includes a ... term loan facility.  The previous credit agreement was comprised ... $300 million term loan.  Each new facility matures on ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... Jan. 28 Repligen Corporation (Nasdaq: RGEN ... with GE Healthcare Bio-Sciences AB by entering into a five-year ... the manufacture of monoclonal antibodies, a highly successful class of ... A and has manufactured recombinant Protein A for GE Healthcare ...
... , , , ... 9th year, the ePharma,Summit ( http://www.epharmasummit.com ), to be held ... PA ,continues to be the most,innovative digital marketing event ... from leading pharmaceutical,companies attend ePharma Summit for incomparable access to ...
Cached Medicine Technology:Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A 2Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A 3MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 2MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 3
(Date:6/18/2013)... (PRWEB) June 18, 2013 David Connett, ... of Family Medicine for the College of Osteopathic Medicine ... Sciences has been elected president of the Osteopathic ... G. Brown Jr. appointed Connett, a 1984 alumnus of ... members recently elected Connett to the position during a ...
(Date:6/18/2013)... the mammary gland appear to provide a crucial link ... and the subsequent development of breast cancer, researchers from ... issue of the journal Cancer Prevention Research . ... with an increased risk of certain types of aggressive ... social stress to cancer have been hard to identify. ...
(Date:6/18/2013)... discovered a way to make phytosterol molecules from plants ... humans, potentially opening the way to dramatic reductions in ... the new process and composition was issued on June ... molecules in animals are highly similar and when both ... When they mix in the gut of an animal, ...
(Date:6/18/2013)... fitness training system using a person,s DNA was ... the LeWeb,13 London Startup Competition, Europe,s largest technology ... Genetrainer, building on University of Bristol research by ... Julian Gough, Professor of Bioinformatics in the University,s ... 350 startups to be one of 16 finalists ...
(Date:6/18/2013)... 2013 Dr. Farooq Ashraf, an Atlanta ... Institute, is pleased to announce that he is offering ... LASIK equipment, the iFS™ Advanced Femtosecond Laser. Currently, the ... Atlanta to offer its patients this new technology, and ... patients a complimentary upgrade to the Advanced Femtosecond Laser. ...
Breaking Medicine News(10 mins):Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4Health News:Brandeis scientist invents anti-cholesterol process 2Health News:Atlanta LASIK Surgeon Offers New LASIK Technology 2
... arrests and then receive coronary angiography are twice as ... those who don,t have the procedure, according to a ... The study, published in the May/June issue of the ... available online, showed that patient outcomes improved with coronary ...
... expensive treatment laterHARRISBURG, Pa., March 31 As the ... their expenses, the Pennsylvania Dental Association (PDA) is stressing ... up with their oral health care."The PDA understands how ... ends meet in economic hard times, especially those facing ...
... 31 Dynatronics Corporation (Nasdaq: DYNT ) ... period extension with the SEC, giving the company until ... per share minimum bid rule."We are pleased that NASDAQ ... H. Cullimore Jr., chairman and president of Dynatronics. "This ...
... packages barrage consumers with information, some required to ... brand names still overshadow critical fine print on ... , In a study to be published in ... Science , MSU researchers examined the effectiveness of ...
... Cold Spring Harbor Laboratory (CSHL) and 20 other major research ... challenge to the neuroscience community. At long last, the ... assemble a comprehensive map of the major neural circuits in ... genomes of many organisms, including that of humans, have been ...
... Surgery 2008 Procedural Survey shows a 2% decrease in ... time in several years, male cosmetic surgery has declined ... Surgery (AACS), a leader in the cosmetic surgery industry, ... that males are cutting back on cosmetic procedures. ...
Cached Medicine News:Health News:Coronary angiography may improve outcomes for cardiac arrest patients 2Health News:Coronary angiography may improve outcomes for cardiac arrest patients 3Health News:Pennsylvania Dental Association Cautions Patients: Don't Forgo Dental Visits Because of the Economy 2Health News:NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance 2Health News:Researchers question effectiveness of warning labels on over-the-counter drugs 2Health News:Researchers question effectiveness of warning labels on over-the-counter drugs 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 2Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 4Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 5Health News:Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Medicine Products: